Arisa Ortiz, MD
Dermatology · San Diego, CANPI 1659556165
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $169,316 of the $261,290 with a category attached, or 64.8%. AbbVie accounts for 88.6% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $46,462 and has fallen 94.8% since, to $2,417 in 2025. Among dermatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 163 payments — averaging $1603.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$232K
- Merz North America, Inc.$9K
- Endo Pharmaceuticals Inc.$9K
- Galderma Laboratories, L.p.$8K
- Solta Medical, A Division Of Bausch Health US, LLC$2K
- Aclaris Therapeutics, Inc.$2K
- plus $386 from 5 others
Across 25 payments — averaging $16,650 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$397K
- Endo Pharmaceuticals Inc.$19K
What the payments were for
- Consulting fees$169,31665%
- Speaking & faculty fees$18,4107%
- Grants$47,50018%
- Travel & lodging$21,6438%
- Food & beverage$4,2282%
- Education$1940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 117 | $231,553 |
| Merz North America, Inc. | 20 | $9,418 |
| Endo Pharmaceuticals Inc. | 11 | $8,830 |
| Galderma Laboratories, L.p. | 5 | $7,534 |
| Solta Medical, A Division Of Bausch Health US, LLC | 1 | $2,010 |
| Aclaris Therapeutics, Inc. | 3 | $1,559 |
| Revance Therapeutics, Inc. | 2 | $199 |
| Aurinia Pharma U.S., Inc. | 1 | $116 |
| Kerecis Limited | 1 | $41 |
| Biofrontera Inc. | 1 | $17 |
| Apyx Medical Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$261,290 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 37 | $654 |
| Doxycycline Hyclate | 12 | $61 |
Paid to pharmacies, not to this prescriber.
Other dermatology in San Diego
- Neal BhatiaSan Diego$2.5M
- Michael BradshawSan Diego$143K
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- April ArmstrongLos Angeles$2.3M
- Jeffrey CrowleyBakersfield$2.1M
- Jashin WuCorona$2M
- Raja SivamaniSacramento$1.9M
- Tien NguyenFountain Valley$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.